Oncomatryx Biopharma
Biopharmaceutical company focused on the tumor microenvironment, and developeds precision drugs and diagnostic devices.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD90—135m (Dealroom.co estimates Apr 2022.)
Company register number B95586780
Derio Basque Country (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | 4.4m | 1.2m | 1.3m |
| % growth | 1 % | (73 %) | 10 % | 10943 % | 1124 % | (73 %) | 5 % |
| EBITDA | (<1m) | (<1m) | (<1m) | (<1m) | 3.1m | (1.1m) | - |
| % EBITDA margin | (6477 %) | (23613 %) | (21518 %) | (98 %) | 70 % | (93 %) | - |
| Profit | (1.5m) | (1.9m) | (1.7m) | (2.2m) | <1m | (2.9m) | - |
| % profit margin | (13444 %) | (63420 %) | (52765 %) | (604 %) | 14 % | (246 %) | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
€60.0k | Grant | ||
N/A | Support Program | ||
€39.5k | Grant | ||
€35.1k | Grant | ||
* | €4.5m | Early VC | |
€60.0k | Grant | ||
€23.7k | Grant | ||
€27.7k | Grant | ||
* | $9.0m | Early VC | |
€28.4k | Grant | ||
* | €15.0m | Series A | |
| Total Funding | CAD41.9m | ||
Related Content
Recent News about Oncomatryx Biopharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Oncomatryx Biopharma
Edit
ACQUISITION by Oncomatryx Biopharma May 2023